Literature DB >> 16328505

Human gene therapy and imaging in neurological diseases.

Andreas H Jacobs1, Alexandra Winkler, Maria G Castro, Pedro Lowenstein.   

Abstract

Molecular imaging aims to assess non-invasively disease-specific biological and molecular processes in animal models and humans in vivo. Apart from precise anatomical localisation and quantification, the most intriguing advantage of such imaging is the opportunity it provides to investigate the time course (dynamics) of disease-specific molecular events in the intact organism. Further, molecular imaging can be used to address basic scientific questions, e.g. transcriptional regulation, signal transduction or protein/protein interaction, and will be essential in developing treatment strategies based on gene therapy. Most importantly, molecular imaging is a key technology in translational research, helping to develop experimental protocols which may later be applied to human patients. Over the past 20 years, imaging based on positron emission tomography (PET) and magnetic resonance imaging (MRI) has been employed for the assessment and "phenotyping" of various neurological diseases, including cerebral ischaemia, neurodegeneration and brain gliomas. While in the past neuro-anatomical studies had to be performed post mortem, molecular imaging has ushered in the era of in vivo functional neuro-anatomy by allowing neuroscience to image structure, function, metabolism and molecular processes of the central nervous system in vivo in both health and disease. Recently, PET and MRI have been successfully utilised together in the non-invasive assessment of gene transfer and gene therapy in humans. To assess the efficiency of gene transfer, the same markers are being used in animals and humans, and have been applied for phenotyping human disease. Here, we review the imaging hallmarks of focal and disseminated neurological diseases, such as cerebral ischaemia, neurodegeneration and glioblastoma multiforme, as well as the attempts to translate gene therapy's experimental knowledge into clinical applications and the way in which this process is being promoted through the use of novel imaging approaches.

Entities:  

Mesh:

Year:  2005        PMID: 16328505      PMCID: PMC2902257          DOI: 10.1007/s00259-005-1960-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  255 in total

1.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

Authors:  J H Kordower; M E Emborg; J Bloch; S Y Ma; Y Chu; L Leventhal; J McBride; E Y Chen; S Palfi; B Z Roitberg; W D Brown; J E Holden; R Pyzalski; M D Taylor; P Carvey; Z Ling; D Trono; P Hantraye; N Déglon; P Aebischer
Journal:  Science       Date:  2000-10-27       Impact factor: 47.728

2.  A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.

Authors:  R J Parks; L Chen; M Anton; U Sankar; M A Rudnicki; F L Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

3.  Mapping of a gene for Parkinson's disease to chromosome 4q21-q23.

Authors:  M H Polymeropoulos; J J Higgins; L I Golbe; W G Johnson; S E Ide; G Di Iorio; G Sanges; E S Stenroos; L T Pho; A A Schaffer; A M Lazzarini; R L Nussbaum; R C Duvoisin
Journal:  Science       Date:  1996-11-15       Impact factor: 47.728

4.  Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas.

Authors:  K S Aboody; A Brown; N G Rainov; K A Bower; S Liu; W Yang; J E Small; U Herrlinger; V Ourednik; P M Black; X O Breakefield; E Y Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

5.  Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.

Authors:  Y Shen; S I Muramatsu; K Ikeguchi; K I Fujimoto; D S Fan; M Ogawa; H Mizukami; M Urabe; A Kume; I Nagatsu; F Urano; T Suzuki; H Ichinose; T Nagatsu; J Monahan; I Nakano; K Ozawa
Journal:  Hum Gene Ther       Date:  2000-07-20       Impact factor: 5.695

6.  Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses.

Authors:  A M Sandmair; S Loimas; P Puranen; A Immonen; M Kossila; M Puranen; H Hurskainen; K Tyynelä; M Turunen; R Vanninen; P Lehtolainen; L Paljärvi; R Johansson; M Vapalahti; S Ylä-Herttuala
Journal:  Hum Gene Ther       Date:  2000-11-01       Impact factor: 5.695

7.  Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia.

Authors:  M D Linnik; P Zahos; M D Geschwind; H J Federoff
Journal:  Stroke       Date:  1995-09       Impact factor: 7.914

8.  Imaging the expression of transfected genes in vivo.

Authors:  J G Tjuvajev; G Stockhammer; R Desai; H Uehara; K Watanabe; B Gansbacher; R G Blasberg
Journal:  Cancer Res       Date:  1995-12-15       Impact factor: 12.701

9.  Clinical and [18F] dopa PET findings in early Parkinson's disease.

Authors:  P K Morrish; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

10.  Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration.

Authors:  M H Tuszynski; J Roberts; M C Senut; H S U; F H Gage
Journal:  Gene Ther       Date:  1996-04       Impact factor: 5.250

View more
  4 in total

Review 1.  Strategies to improve drug delivery across the blood-brain barrier.

Authors:  Albertus G de Boer; Pieter J Gaillard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  The value of EGFRvIII as the target for glioma vaccines.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

Review 3.  Neuronal networks in mental diseases and neuropathic pain: Beyond brain derived neurotrophic factor and collapsin response mediator proteins.

Authors:  Tam T Quach; Jessica K Lerch; Jerome Honnorat; Rajesh Khanna; Anne-Marie Duchemin
Journal:  World J Psychiatry       Date:  2016-03-22

4.  Quantitative, noninvasive, in vivo longitudinal monitoring of gene expression in the brain by co-AAV transduction with a PET reporter gene.

Authors:  Sea Young Yoon; Carlos Gay-Antaki; Datta E Ponde; Harish Poptani; Charles H Vite; John H Wolfe
Journal:  Mol Ther Methods Clin Dev       Date:  2014-06-04       Impact factor: 5.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.